Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer.

Al-Samsam S, Bartos J, Samal V, Dvorak J, Kolarova H, Richter I

DOI: 10.5603/rpor.99028
Published: 2024
Container: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.5603/rpor.99028,
  title = {Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer.},
  author = {Al-Samsam S and Bartos J and Samal V and Dvorak J and Kolarova H and Richter I},
  year = {2024},
  journal = {Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology},
  doi = {10.5603/rpor.99028},
  url = {https://doi.org/10.5603/rpor.99028}
}

RIS

TY  - JOUR
TI  - Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer.
AU  - Al-Samsam S
AU  - Bartos J
AU  - Samal V
AU  - Dvorak J
AU  - Kolarova H
AU  - Richter I
PY  - 2024
JO  - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
DO  - 10.5603/rpor.99028
UR  - https://doi.org/10.5603/rpor.99028
ER  -

APA

S, A., J, B., V, S., J, D., H, K., & I, R. (2024). Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer.. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. https://doi.org/10.5603/rpor.99028

Source records

pubmed · retrieved 2026-09-26T20:57:19.173Z